Match tier
Listed
Presence
Current · Arkansas
Last published
2021
Sources
OpenAlex · ORCID
Refreshed
2026-10-08
C
Charles E. Hay
Role not yet determined Is this you? Add your title
Also affiliated: Children's Hospital of Philadelphia (2020); University of Pennsylvania (2020)
2 h-index
9 pubs
35 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Charles E. Hay's research investigates the impact of drug exposure on the immune system. His work has explored how antibody gene therapy can counteract the immunosuppressive effects of substances like MDMA in animal models. This research contributes to understanding the complex interactions between pharmacological agents and peripheral immune responses.
Metrics
- h-index: 2
- Publications: 9
- Citations: 35
Selected Publications
-
Antibody Gene Therapy Mitigates the immunosuppressive effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in the periphery of Male BALB/c Mice (2021)
-
Antibody Gene Therapy Mitigates Adverse Immunological Effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in Male BALB/c Mice (2020)
-
The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse (2020)
-
AAV‐7F9‐Fc Protects Against METH‐Induced Hyperthermia and Decreases in Blood Brain Barrier Tight Junction Expression in a Rodent Model (2019)
-
The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse (2019)
-
Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment (2018)
-
Anti‐Methamphetamine Antibody Gene Therapy Protects Against Some METH‐Induced Inflammation (2018)
-
Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse (2018)
Collaboration Network
Top Collaborators
Eric C. Peterson
University of Arkansas for Medical Sciences (US)
8 shared publications
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
- Antibody Gene Therapy Mitigates Adverse Immunological Effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in Male BALB/c Mice
- Antibody Gene Therapy Mitigates the immunosuppressive effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in the periphery of Male BALB/c Mice
Showing 5 of 8 shared publications
Caleb Bolden
University of Arkansas for Medical Sciences (US)
7 shared publications
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
- Antibody Gene Therapy Mitigates Adverse Immunological Effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in Male BALB/c Mice
- Antibody Gene Therapy Mitigates the immunosuppressive effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in the periphery of Male BALB/c Mice
Showing 5 of 7 shared publications
Laura Ewing
University of Arkansas for Medical Sciences
5 shared publications
In database
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
- Anti‐Methamphetamine Antibody Gene Therapy Protects Against Some METH‐Induced Inflammation
- Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment
Paris Margaritis
Children's Hospital of Philadelphia (US)
5 shared publications
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
- Anti‐Methamphetamine Antibody Gene Therapy Protects Against Some METH‐Induced Inflammation
- Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment
Michael D. Hambuchen
University of Arkansas for Medical Sciences (US)
4 shared publications
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
- Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment
S. Michael Owens
University of Arkansas for Medical Sciences
4 shared publications
In database
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
- Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment
Shannon M. Zintner
Children's Hospital of Philadelphia
2 shared publications
In database
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
Juliana C. Small
Children's Hospital of Philadelphia (US)
2 shared publications
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
William E. Fantegrossi
Children's Hospital of Philadelphia
2 shared publications
In database
- The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse
- The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse
Cameron Tilley
University of Arkansas for Medical Sciences (US)
2 shared publications
- Antibody Gene Therapy Mitigates Adverse Immunological Effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in Male BALB/c Mice
- Antibody Gene Therapy Mitigates the immunosuppressive effects of 3,4‐Methylenedioxymethamphetamine (MDMA) in the periphery of Male BALB/c Mice
Kennede McLeroy‐Charles
University of Arkansas for Medical Sciences
2 shared publications
In database
- AAV‐7F9‐Fc Protects Against METH‐Induced Hyperthermia and Decreases in Blood Brain Barrier Tight Junction Expression in a Rodent Model
- Anti‐Methamphetamine Antibody Gene Therapy Protects Against Some METH‐Induced Inflammation
G. González
University of Arkansas for Medical Sciences (US)
1 shared publication
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
Emily E. Reichard
University of Arkansas for Medical Sciences (US)
1 shared publication
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
Nisha Nanaware‐Kharade
University of Arkansas for Medical Sciences (US)
1 shared publication
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
Sinthia Alam
University of Arkansas for Medical Sciences (US)
1 shared publication
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse
Similar Researchers
Based on overlapping research topics
John T. Striednig
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
C. Keisling
Harding University Main Campus
Pharmacological Effects and Toxicity Studies
Immune Response and Inflammation
Neuroscience and Neuropharmacology Research
Justin M. Pressley
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Immune Response and Inflammation
Neuroscience and Neuropharmacology Research
Justin R. Nickell
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
Brenda M. Gannon
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
Michael D. Berquist
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes